KR20140135198A - Pak1 억제제로 흑색종을 치료하는 방법 - Google Patents

Pak1 억제제로 흑색종을 치료하는 방법 Download PDF

Info

Publication number
KR20140135198A
KR20140135198A KR20147025466A KR20147025466A KR20140135198A KR 20140135198 A KR20140135198 A KR 20140135198A KR 20147025466 A KR20147025466 A KR 20147025466A KR 20147025466 A KR20147025466 A KR 20147025466A KR 20140135198 A KR20140135198 A KR 20140135198A
Authority
KR
South Korea
Prior art keywords
melanoma
pak1
inhibitor
braf
patient
Prior art date
Application number
KR20147025466A
Other languages
English (en)
Korean (ko)
Inventor
클라우스 피 회프리치
애드리안 엠 저브
하르트무트 코에펜
크리스티 씨 옹
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20140135198A publication Critical patent/KR20140135198A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR20147025466A 2012-03-16 2013-03-13 Pak1 억제제로 흑색종을 치료하는 방법 KR20140135198A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612202P 2012-03-16 2012-03-16
US61/612,202 2012-03-16
PCT/EP2013/055085 WO2013135745A1 (en) 2012-03-16 2013-03-13 Methods of treating melanoma with pak1 inhibitors

Publications (1)

Publication Number Publication Date
KR20140135198A true KR20140135198A (ko) 2014-11-25

Family

ID=47846052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147025466A KR20140135198A (ko) 2012-03-16 2013-03-13 Pak1 억제제로 흑색종을 치료하는 방법

Country Status (10)

Country Link
EP (1) EP2844248A1 (zh)
JP (1) JP2015511598A (zh)
KR (1) KR20140135198A (zh)
CN (1) CN104168898A (zh)
BR (1) BR112014020173A8 (zh)
CA (1) CA2860994A1 (zh)
HK (1) HK1200093A1 (zh)
MX (1) MX2014010953A (zh)
RU (1) RU2014141018A (zh)
WO (1) WO2013135745A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139331A1 (en) * 2015-03-05 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of melanoma
KR101730595B1 (ko) 2015-03-18 2017-05-11 충북대학교 산학협력단 Pak4 억제제를 유효성분으로 포함하는 미백 및 멜라닌 색소 과다 침착 질환의 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP0229046B1 (fr) 1985-03-30 1994-05-04 BALLIVET, Marc Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
AU668347B2 (en) 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU7104294A (en) 1994-06-10 1996-01-05 Symbiotech, Inc. Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
JPH11511977A (ja) 1995-09-07 1999-10-19 ノボ ノルディスク アクティーゼルスカブ 洗剤酵素活性についてのファージ・ディスプレー
AU715608B2 (en) 1996-03-20 2000-02-03 Morphosys Ag Purification of tissue plasminogen activator (tPA)
WO1997046251A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
AU735015B2 (en) 1996-06-10 2001-06-28 Scripps Research Institute, The Use of substrate subtraction libraries to distinguish enzyme specificities
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
EP0929361A4 (en) 1996-10-04 2000-07-19 Whatman Inc DEVICE AND METHOD FOR SIMULTANEOUS MULTIPLE SYNTHESIS
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
CA2270869A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1141708A1 (en) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Identifying small organic molecule ligands for binding
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
IL151781A0 (en) 2000-03-16 2003-04-10 Genetica Inc Methods and compositions for rna interference
WO2004007504A1 (en) 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
MX2007008385A (es) * 2005-01-10 2007-08-21 Pfizer Pirrolopirazoles, potentes inhibidores de cinasa.
MX2007012448A (es) 2005-04-06 2007-10-19 Astrazeneca Ab Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak.
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
DK1979356T3 (da) 2005-12-21 2013-11-18 Pfizer Prod Inc Carbonylaminopyrrolopyrazoler, kraftige kinaseinhibitorer
WO2009086204A2 (en) 2007-12-21 2009-07-09 Afraxis, Inc. Methods for treating neuropsychiatric conditions
ES2306630B1 (es) 2008-07-17 2009-06-03 Encarnacion Mira Rodriguez Dispositivo antiflacidez y antiarrugas.
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
WO2011044264A2 (en) 2009-10-06 2011-04-14 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
EA201270498A1 (ru) 2009-10-09 2012-11-30 Афраксис, Инк. 8-этил-6-(арил)пиридо[2,3-d]пиримидин-7(8h)-оны для лечения заболеваний цнс
WO2011156646A2 (en) 2010-06-09 2011-12-15 Afraxis, Inc. 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156640A2 (en) 2010-06-09 2011-12-15 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
US20130338153A1 (en) 2010-06-10 2013-12-19 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156780A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156786A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Also Published As

Publication number Publication date
EP2844248A1 (en) 2015-03-11
RU2014141018A (ru) 2016-05-10
BR112014020173A2 (zh) 2017-06-20
HK1200093A1 (zh) 2015-07-31
JP2015511598A (ja) 2015-04-20
MX2014010953A (es) 2014-10-13
CN104168898A (zh) 2014-11-26
CA2860994A1 (en) 2013-09-19
BR112014020173A8 (pt) 2017-07-11
WO2013135745A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
US11081236B2 (en) Diagnostic and therapeutic methods for the treatment of breast cancer
Zhang et al. The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1
JP6900314B2 (ja) 膀胱癌の治療、診断、及び予後判定方法
Fedorenko et al. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
CN109844536B (zh) 预测对pd-1轴抑制剂的响应
JP2023182572A (ja) がんの診断及び治療方法
JP2019531699A (ja) Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
KR20180134347A (ko) 암의 진단 및 치료 방법
Mahadevan et al. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2
Lang et al. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia
WO2013122609A1 (en) Methods of using cdk8 antagonists
US20220313700A1 (en) Methods for treating map3k8 positive cancers
US11696924B2 (en) Combination therapy using PDK1 and PI3K inhibitors
US20230383365A1 (en) Cancer treatments and methods of selecting same
KR20230015888A (ko) 사시투주맙 고비테칸 요법에 대한 바이오마커
May et al. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
Borneman et al. Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
KR20140135198A (ko) Pak1 억제제로 흑색종을 치료하는 방법
Martin-Broto et al. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
CN115003334A (zh) 胰腺癌的治疗和预后
US20230076415A1 (en) Methods and compositions for treating melanoma
Dammert Characterization and therapeutic exploitation of molecular vulnerabilities in genetically defined lung cancer
LEPORE SIGNORILE p38α, the β-catenin chromatin associated kinase, as promising target in colorectal cancer stem cells for personalized therapy
Triscott Polo-like kinase 1 as a prognostic and therapeutic target in high-grade brain tumors
Hajdúch Identification and Characterization of Molecular Basis of Cancer Cell Drug Resistance Mechanisms towards Aurora Kinase Inhibitors CYC116 and ZM447439

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid